These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 31819247)

  • 1. Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
    Gulamhusein AF; Hirschfield GM
    Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):93-110. PubMed ID: 31819247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapies target the toxic consequences of cholestatic liver disease.
    Jansen PLM
    Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Treatment Options for Primary Biliary Cholangitis.
    Wong KA; Bahar R; Liu CH; Bowlus CL
    Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and potential treatments for primary biliary cholangitis.
    Shah RA; Kowdley KV
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary biliary cirrhosis in adults.
    Momah N; Lindor KD
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):427-33. PubMed ID: 24580040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New name and new treatments for primary biliary cholangitits].
    Bossen L; Ytting H; Jepsen P; Hamberg O; Ott P; Grønbæk H
    Ugeskr Laeger; 2018 Mar; 180(10):. PubMed ID: 29536837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
    Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
    Front Immunol; 2022; 13():940688. PubMed ID: 35880178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
    Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
    Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
    Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
    Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary biliary cholangitis: A tale of epigenetically-induced secretory failure?
    Rodrigues PM; Perugorria MJ; Santos-Laso A; Bujanda L; Beuers U; Banales JM
    J Hepatol; 2018 Dec; 69(6):1371-1383. PubMed ID: 30193962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
    BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrates for Primary Biliary Cholangitis: What's All the Hype?
    Levy C
    Ann Hepatol; 2017; 16(5):704-706. PubMed ID: 28809729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid.
    van Hooff MC; Werner E; van der Meer AJ
    Eur J Intern Med; 2024 Jun; 124():14-21. PubMed ID: 38307734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.